TY - JOUR
T1 - Gene therapy for carcinoma of the breast
AU - Stoff-Khalili, M. A.
AU - Dall, P.
AU - Curiel, D. T.
N1 - Funding Information:
This work was supported by Grant of the Deutsche Forschungsgemeinschaft Sto 647/1-1 (to MA Stoff-Khalili), grants from the National Institutes of Health: RO1CA08382-05A1, RO1CA111569-01A1, and Department of Defense: W81XWH-05-1-0035 (to DT Curiel). Dr M Everts is thanked for critically reading the manuscript.
PY - 2006/7/17
Y1 - 2006/7/17
N2 - In view of the limited success of available treatment modalities for breast cancer, alternative and complementary strategies need to be developed. The delineation of the molecular basis of breast cancer provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purposes. In this regard, several gene therapy approaches for carcinoma of the breast have been developed. These approaches can be divided into six broad categories: (1) mutation compensation, (2) molecular chemotherapy, (3) proapoptotic gene therapy, (4) antiangiogenic gene therapy, (5) genetic immunopotentiation, and (6) genetic modulation of resistance/sensitivity. Clinical trials for breast cancer have been initiated to evaluate safety, toxicity, and efficacy. Combined modality therapy with gene therapy and chemotherapy or radiation therapy has shown promising results. It is expected that as new therapeutic targets and approaches are identified and advances in vector design are realized, gene therapy will play an increasing role in clinical breast cancer treatment.
AB - In view of the limited success of available treatment modalities for breast cancer, alternative and complementary strategies need to be developed. The delineation of the molecular basis of breast cancer provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purposes. In this regard, several gene therapy approaches for carcinoma of the breast have been developed. These approaches can be divided into six broad categories: (1) mutation compensation, (2) molecular chemotherapy, (3) proapoptotic gene therapy, (4) antiangiogenic gene therapy, (5) genetic immunopotentiation, and (6) genetic modulation of resistance/sensitivity. Clinical trials for breast cancer have been initiated to evaluate safety, toxicity, and efficacy. Combined modality therapy with gene therapy and chemotherapy or radiation therapy has shown promising results. It is expected that as new therapeutic targets and approaches are identified and advances in vector design are realized, gene therapy will play an increasing role in clinical breast cancer treatment.
KW - Breast cancer
KW - Carcinogenesis
KW - Gene therapy
KW - Immunotherapy
KW - Suicide gene therapy
UR - http://www.scopus.com/inward/record.url?scp=33747695784&partnerID=8YFLogxK
U2 - 10.1038/sj.cgt.7700929
DO - 10.1038/sj.cgt.7700929
M3 - Review article
C2 - 16410823
AN - SCOPUS:33747695784
SN - 0929-1903
VL - 13
SP - 633
EP - 647
JO - Cancer gene therapy
JF - Cancer gene therapy
IS - 7
ER -